Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 250-254

  Liu, Cui Qing ^a,b,c   Leung, Fung Ping ^c   Lee, Vivian Wing Yan ^c   Lau, Chi Wai ^c   Yao, Xiaoqiang ^c   Lu, Limin ^a   Huang, Yu ^c  

^a FUDAN UNIVERSITY   (China)

^b HANGZHOU NORMAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aorta (rat); Nitrate tolerance; Nitroglycerin; Phosphodiesterase

Indexed keywords

BQ 610; CILOSTAZOL; CYCLIC GMP; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; INDOMETACIN; PHENYLEPHRINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROLIPRAM; T 0156; TERUTROBAN; THROMBOXANE A2; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; ENZYME IMMUNOASSAY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 48049094581     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.009     Document Type: Article

References (23)

1. Artz J.D., Schmidt B., McCracken J.L., and Marletta M.A. Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance. J. Biol. Chem. 277 (2002) 18253-18256
2. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
3. Cawley S.M., Sawyer C.L., Brunelle K.F., van der Vliet A., and Dostmann W.R. Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell Signal. 19 (2007) 1023-1033
4. 2+ sensitivity and partially by repolarization. Am. J. Physiol. 271 (1996) H962-H968
5. Coskun B., Soylemez S., Parlar A.I., Tulga Ulus A., Fehmi Katircioglu S., and Akar F. Effect of resveratrol on nitrate tolerance in isolated human internal mammary artery. J. Cardiovasc. Pharmacol. 47 (2006) 437-445
6. Dikalov S., Fink B., Skatchkov M., Sommer O., and Bassenge E. Formation of reactive oxygen species in various vascular cells during glyceryltrinitrate metabolism. J. Cardovasc. Pharmacol. Ther. 3 (1998) 51-62
7. Dou D., Zheng X., Qin X., Qi H., Liu L., Liu L., Raj J.U., and Gao Y. Role of cGMP-dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries. Br. J. Pharmacol. 153 (2008) 497-507
8. Ghatta S., Hemmer R.B., Uppala S., and O'Rourke S.T. Role of endogenous hydrogen peroxide in the development of nitrate tolerance. Vasc. Pharmacol. 46 (2007) 247-252
9. Hink U., Oelze M., Kolb P., Bachschmid M., Zou M.H., Daiber A., Mollnau H., August M., Baldus S., Tsilimingas N., Walter U., Ullrich V., and Münzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J. Am. Coll. Cardiol. 42 (2003) 1826-1834
10. Kass D.A., Takimoto E., Nagayama T., and Champion H.C. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 75 (2007) 303-314
11. Kim D., Rybalkin S.D., Pi X., Wang Y., Zhang C., Munzel T., Beavo J.A., Berk B.C., and Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104 (2001) 2338-2343
12. Kukovetz W.R., Holzmann S., and Schmidt K. Cellular mechanisms of action of therapeutic nitric oxide donors. Eur. Heart J. 12 Suppl E (1991) 16-24
13. Kurz S., Hink U., Nickenig G., Borthayre A.B., Harrison D.G., and Munzel T. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 99 (1999) 3181-3187
14. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
15. MacPherson J.D., Gillespie T.D., Dunkerley H.A., Maurice D.H., and Bennett B.M. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J. Pharmacol. Exp. Ther. 317 (2006) 188-195
16. Mochida H., Takagi M., Inoue H., Noto T., Yano K., Fujishige K., Sasaki T., Yuasa K., Kotera J., Omori K., and Kikkawa K. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmacol. 456 (2002) 91-98
17. Mülsch A., Oelze M., Klöss S., Mollnau H., Töpfer A., Smolenski A., Walter U., Stasch J.P., Warnholtz A., Hink U., Meinertz T., and Münzel T. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 103 (2001) 2188-2194
18. Münzel T., Daiber A., and Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 97 (2005) 618-628
19. Münzel T., Giaid A., Kurz S., Stewart D.J., and Harrison D.G. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc. Natl. Acad. Sci. USA 92 (1995) 5244-5248
20. Omura T., Matsumoto T., Nakae I., Takahashi M., and Kinoshita M. Two possible mechanisms underlying nitrate tolerance in monkey coronary arteries. Clin. Exp. Pharmacol. Physiol. 28 (2001) 259-265
21. Pagani E.D., VanAller G.S., O'Connor B., and Silver P.J. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur. J. Pharmacol. 243 (1993) 141-147
22. Sydow K., Daiber A., Oelze M., Chen Z., August M., Wendt M., Ullrich V., Mülsch A., Schulz E., Keaney J.F., Stamler J.S., and Münzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Invest. 113 (2004) 482-489
23. Zou M.H. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid. Mediat. 82 (2007) 119-127